Cannabidiol and Epilepsy: The Real Risks and Benefits

Wednesday, October 24, 2018
2:00 pm - 4:00 am CST
Web Event

Recently, there has been a great deal of focus on the uses and risks of marijuana in the field of epilepsy. Epidiolex, a treatment of cannabidiol (CBD), recently gained FDA approval for the treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome, two rare and severe forms of epilepsy. This is the first FDA-approved plant based treatment with greater than 98% CBD.

Unlike THC, one of the other components in marijuana, CBD does not cause the euphoria (the “high”) that comes from THC.

In this webinar, you will learn why CBD may be an effective treatment for certain types of epilepsy, what risks can be associated with CBD, and what the FDA approval of means for the future of epilepsy research and treatment.

Featured Presenter: Anup D. Patel, MD, is Section Chief of Pediatric Neurology at Nationwide Children’s and Associate Professor of Clinical Pediatrics and Neurology at The Ohio State University College of Medicine

This webinar is made possible thanks to the generous funding provided by Sunovion Pharmaceuticals.

CURE’S LEADERS IN EPILEPSY RESEARCH WEBINAR SERIES

This program brings together top epilepsy researchers for a series of webinars providing cutting-edge information about new discoveries, research, and treatments in epilepsy. Researchers discuss the real-life challenges faced by the epilepsy community and potential resources to address those needs.

Sponsored by

  • image-sponsors